Ongoing Clinical Trials
FLOW: Effect of Semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease
FLOW is a multi-center, international, randomized, double-blind, parallel-group, placebo-controlled trial comparing the medication, Semaglutide 1.0 mg, versus placebo, both administered subcutaneously once weekly, and added to standard-of-care in subjects with Type-2 Diabetes and pre-existing Chronic Kidney Disease. Objectives includes: to demonstrate that Semaglutide delays the progression of renal impairment and lowers the risk of renal and cardiovascular mortality compared to placebo; and to compare the effect of treatment with Semaglutide versus placebo, both added to standard-of-care in subjects with type 2 diabetes and chronic kidney disease with regards to cardiovascular morbidity, peripheral artery disease, glycemic control, body weight, blood pressure and safety.
PERL Skeletal Health Study
PERL Skeletal Health Study (Follow-up Study):
PERL Skeletal is a PERL follow-up study. The PERL Skeletal Study is being conducted to investigate the effects of Type 1 Diabetes on skeletal and bone health within a population in which kidney function is well known.This is an observational, multicenter, prospective, post-RCT (Randomized Control Trial) cohort study.
REMIT-IDegLira: Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes with IDegLira
Approximately 1 in 10 adults in Canada currently have diagnosed diabetes. Recent research suggests that it may be possible to reverse type 2 diabetes or put it into remission using intensive lifestyle therapy and short-term combination drug therapy with injectable insulin and oral diabetes medications. This trial will test whether a short treatment with a combined basal insulin degludec and Liraglutide (IDegLira), metformin, and lifestyle is able to achieve prolonged diabetes remission.
Semaglutide effects on cardiovascular outcomes in people with overweight or obesity
Semaglutide is a medicine that may be prescribed in some countries to treat Type-2 Diabetes. A completed study showed that Semaglutide reduced the risk of cardiovascular events in patients with T2DM. In the SELECT clinical trial, the study doctors will check to see if Semaglutide may reduce the risk of future cardiovascular events in patients without diabetes, but with overweight or obesity.